Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12017471 | 0.83 | CHRM2 (0.42) | CHRM2CHRM1ALDH1A1MAPTGAA | |
| SCHEMBL24575471 | 0.83 | KCNH2 (0.50) | CHRM2CHRM1KCNH2SCN5AALDH1A1 | |
| SCHEMBL1547447 | 0.81 | CA1 (0.52) | CHRM2CHRM1ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL7196230 | 0.81 | SCN5A (0.57) | KCNH2SCN5AALDH1A1CACNA1CKDM4E | |
| SCHEMBL27839986 | 0.79 | SCN5A (0.55) | KCNH2SCN5AALDH1A1CACNA1CKDM4E | |
| Hydrochloric Acid SCHEMBL2864438 | 0.79 | SCN5A (0.55) | KCNH2SCN5AALDH1A1CACNA1CKDM4E | |
| SCHEMBL11698602 | 0.78 | CHRM2 (0.41) | CHRM2CHRM1KCNH2SCN5AALDH1A1 | |
| SCHEMBL22169119 | 0.78 | CHRM2 (0.45) | CHRM2CHRM1ALDH1A1MAPTGAA | |
| SCHEMBL17551509 | 0.78 | CHRM2 (0.41) | CHRM2CHRM1KCNH2SCN5AALDH1A1 | |
| SCHEMBL28395567 | 0.76 | ALOX5 (0.49) | CHRM2CHRM1ALOX5PTGS2PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691864-B2 | Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof | HORIZON THERAPEUTICS USA, INC. (SUCCESSOR IN INTEREST TO RAPTOR PHARMACEUTICAL CORP.) | 2014-04-08 | — | — | US | disclosed |
| US-20120295946-A1 | Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof | National Institute of Health (NIH) | 2012-11-22 | — | — | US | disclosed |
| US-8258172-B2 | Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof | RAPTOR PHARMACEUTICAL CORP (US) | 2012-09-04 | — | — | US | disclosed |
| US-20110021594-A1 | Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof | Raptor Pharmaceutical Corp. | 2011-01-27 | — | — | US | disclosed |
| US-7786162-B2 | Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof | Raptor Pharmaceutical Corp. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20090131501-A1 | Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof | TORREYPINES THERAPEUTICS (US) | 2009-05-21 | — | — | US | disclosed |
| EP-1349858-B1 | AGENTS USEFUL FOR REDUCING AMYLOID PRECURSOR PROTEIN AND TREATING DEMANTIA AND METHODS OF USE THEREOF | US GOV HEALTH & HUMAN SERV (US) | 2008-08-27 | — | — | EP | disclosed |
| US-7153882-B2 | Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060270729-A1 | Agents useful for reducing amylioid precursor protein and treating dementia and methods of use thereof | GREIG NIGEL H | 2006-11-30 | — | — | US | disclosed |
| US-20040138282-A1 | Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof | HORIZON THERAPEUTICS USA, INC. (SUCCESSOR IN INTEREST TO RAPTOR PHARMACEUTICAL CORP.) | 2004-07-15 | — | — | US | disclosed |
| EP-1349858-A2 | AGENTS USEFUL FOR REDUCING AMYLOID PRECURSOR PROTEIN AND TREATING DEMANTIA AND METHODS OF USE THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002048150-A2 | AGENTS USEFUL FOR REDUCING AMYLOID PRECURSOR PROTEIN AND TREATING DEMANTIA AND METHODS OF USE THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-06-20 | — | — | WO | disclosed |
| US-4117165-A | ANTIULCER, HYPOTENSIVE AGENTS | WILLIAM H. RORER, INC. (US) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021594-A1 | Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof | APP, BACE1, PSEN1 | CHRM2 231/4885CHRM1 273/4885KCNH2 4510/4885 |
| US-20090131501-A1 | Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof | APP, BACE1, PSEN1 | CHRM2 231/4885CHRM1 273/4885KCNH2 4510/4885 |
| US-20060270729-A1 | Agents useful for reducing amylioid precursor protein and treating dementia and methods of use thereof | IAPP, APP, BACE1 | CHRM2 477/4885CHRM1 730/4885KCNH2 4536/4885 |
| US-20120295946-A1 | Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof | APP, BACE1, PSEN1 | CHRM2 231/4885CHRM1 273/4885KCNH2 4510/4885 |
| US-20040138282-A1 | Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof | APP, BACE1, CTH | CHRM2 684/4885CHRM1 917/4885KCNH2 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.